{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T20:24:57Z","timestamp":1710188697770},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1007\/s12325-014-0133-9","type":"journal-article","created":{"date-parts":[[2014,7,2]],"date-time":"2014-07-02T10:22:29Z","timestamp":1404296549000},"page":"683-695","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Pharmacoeconomics of Granulocyte Colony-Stimulating Factor: A Critical Review"],"prefix":"10.1007","volume":"31","author":[{"given":"Gisoo","family":"Barnes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashutosh","family":"Pathak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee","family":"Schwartzberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,7,3]]},"reference":[{"key":"133_CR1","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJMct1210890","volume":"368","author":"CL Bennett","year":"2013","unstructured":"Bennett CL, Djulbegovic B, Norris LB, Armitage JO. Colony-stimulating factors for febrile neutropenia during cancer therapy. N Engl J Med. 2013;368:1131\u20139.","journal-title":"N Engl J Med"},{"key":"133_CR2","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1002\/cncr.21847","volume":"106","author":"NM Kuderer","year":"2006","unstructured":"Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106:2258\u201366.","journal-title":"Cancer"},{"key":"133_CR3","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2165\/11590130-000000000-00000","volume":"30","author":"BR Hirsch","year":"2012","unstructured":"Hirsch BR, Lyman GH. Pharmacoeconomics of the myeloid growth factors: a critical and systematic review. Pharmacoeconomics. 2012;30:497\u2013511.","journal-title":"Pharmacoeconomics"},{"key":"133_CR4","doi-asserted-by":"crossref","first-page":"859","DOI":"10.3892\/etm.2011.312","volume":"2","author":"MB Schilling","year":"2011","unstructured":"Schilling MB, Parks C, Deeter RG. Costs and outcomes associated with hospitalized cancer patients with neutropenic complications: a retrospective study. Exp Ther Med. 2011;2:859\u201366.","journal-title":"Exp Ther Med"},{"key":"133_CR5","doi-asserted-by":"crossref","first-page":"4524","DOI":"10.1200\/JCO.2003.05.002","volume":"21","author":"GH Lyman","year":"2003","unstructured":"Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol. 2003;21:4524\u201331.","journal-title":"J Clin Oncol"},{"key":"133_CR6","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0959-8049(98)00222-6","volume":"34","author":"GH Lyman","year":"1998","unstructured":"Lyman GH, Kuderer N, Greene J, Balducci L. The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Eur J Cancer. 1998;34:1857\u201364.","journal-title":"Eur J Cancer"},{"key":"133_CR7","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1177\/107327489600300605","volume":"3","author":"J Webster","year":"1996","unstructured":"Webster J, Lyman GH. Use of G-CSF to sustain dose intensity in breast cancer patients receiving adjuvant chemotherapy: a pilot study. Cancer Control. 1996;3:519\u201323.","journal-title":"Cancer Control"},{"key":"133_CR8","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1002\/cncr.20983","volume":"103","author":"V Caggiano","year":"2005","unstructured":"Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer. 2005;103:1916\u201324.","journal-title":"Cancer"},{"key":"133_CR9","first-page":"44","volume":"5","author":"D Weycker","year":"2007","unstructured":"Weycker D, Malin J, Glass A, Oster G. Economic burden of chemotherapy-related febrile neutropenia. J Support Oncol. 2007;5:44\u201355.","journal-title":"J Support Oncol"},{"key":"133_CR10","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/annonc\/mdm525","volume":"19","author":"D Weycker","year":"2008","unstructured":"Weycker D, Malin J, Edelsberg J, Glass A, Gokhale M, Oster G. Cost of neutropenic complications of chemotherapy. Ann Oncol. 2008;19:454\u201360.","journal-title":"Ann Oncol"},{"key":"133_CR11","doi-asserted-by":"crossref","first-page":"809","DOI":"10.2165\/11592980-000000000-00000","volume":"30","author":"SL Michels","year":"2012","unstructured":"Michels SL, Barron RL, Reynolds MW, Smoyer Tomic K, Yu J, Lyman GH. Costs associated with febrile neutropenia in the US. Pharmacoeconomics. 2012;30:809\u201323.","journal-title":"Pharmacoeconomics"},{"key":"133_CR12","doi-asserted-by":"crossref","unstructured":"Weycker D, Malin J, Glass A, Oster G. Cost of chemotherapy-related febrile neutropenia. J Clin Oncol. 2006;24(18s).","DOI":"10.1200\/jco.2006.24.18_suppl.6068"},{"key":"133_CR13","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1592\/phco.21.7.684.34568","volume":"21","author":"SK Gandhi","year":"2001","unstructured":"Gandhi SK, Arguelles L, Boyer JG. Economic impact of neutropenia and febrile neutropenia in breast cancer: estimates from two national databases. Pharmacotherapy. 2001;21:684\u201390.","journal-title":"Pharmacotherapy"},{"key":"133_CR14","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","volume":"47","author":"MS Aapro","year":"2011","unstructured":"Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47:8\u201332.","journal-title":"Eur J Cancer"},{"key":"133_CR15","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1200\/JCO.2005.05.645","volume":"23","author":"OA Clark","year":"2005","unstructured":"Clark OA, Lyman GH, Castro AA, Clark LG, Djulbegovic B. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol. 2005;23:4198\u2013214.","journal-title":"J Clin Oncol"},{"key":"133_CR16","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","volume":"25","author":"NM Kuderer","year":"2007","unstructured":"Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007;25:3158\u201367.","journal-title":"J Clin Oncol"},{"key":"133_CR17","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1093\/annonc\/mdt226","volume":"24","author":"GH Lyman","year":"2013","unstructured":"Lyman GH, Dale DC, Culakova E, Poniewierski MS, Wolff DA, Kuderer NM, et al. The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol. 2013;24:2475\u201384.","journal-title":"Ann Oncol"},{"key":"133_CR18","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00520-001-0312-5","volume":"10","author":"T Berghmans","year":"2002","unstructured":"Berghmans T, Paesmans M, Lafitte JJ, Mascaux C, Meert AP, Jacquy C, et al. Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysis. Support Care Cancer. 2002;10:181\u20138.","journal-title":"Support Care Cancer"},{"key":"133_CR19","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1056\/NEJM199706193362502","volume":"336","author":"LC Hartmann","year":"1997","unstructured":"Hartmann LC, Tschetter LK, Habermann TM, Ebbert LP, Johnson PS, Mailliard JA, et al. Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. N Engl J Med. 1997;336:1776\u201380.","journal-title":"N Engl J Med"},{"key":"133_CR20","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.critrevonc.2007.01.008","volume":"63","author":"C Gridelli","year":"2007","unstructured":"Gridelli C, Aapro MS, Barni S, Beretta GD, Colucci G, Daniele B, et al. Role of colony stimulating factors (CSFs) in solid tumours: results of an expert panel. Crit Rev Oncol Hematol. 2007;63:53\u201364.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"Suppl 5","key":"133_CR21","doi-asserted-by":"crossref","first-page":"v248","DOI":"10.1093\/annonc\/mdq195","volume":"21","author":"J Crawford","year":"2010","unstructured":"Crawford J, Caserta C, Roila F, ESMO Guidelines Working Group. Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. Ann Oncol. 2010;21(Suppl 5):v248\u201351.","journal-title":"Ann Oncol"},{"key":"133_CR22","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/cid\/ciq147","volume":"52","author":"AG Freifeld","year":"2011","unstructured":"Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52:427\u201331.","journal-title":"Clin Infect Dis"},{"key":"133_CR23","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","volume":"24","author":"TJ Smith","year":"2006","unstructured":"Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24:3187\u2013205.","journal-title":"J Clin Oncol"},{"key":"133_CR24","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1200\/JCO.1996.14.9.2511","volume":"14","author":"CL Bennett","year":"1996","unstructured":"Bennett CL, Smith TJ, Weeks JC, Bredt AB, Feinglass J, Fetting JH, et al. Use of hematopoietic colony-stimulating factors: the American Society of Clinical Oncology survey. The Health Services Research Committee of the American Society of Clinical Oncology. J Clin Oncol. 1996;14:2511\u201320.","journal-title":"J Clin Oncol"},{"key":"133_CR25","first-page":"678","volume":"16","author":"SD Ramsey","year":"2010","unstructured":"Ramsey SD, McCune JS, Blough DK, McDermott CL, Clarke L, Malin JL, et al. Colony-stimulating factor prescribing patterns in patients receiving chemotherapy for cancer. Am J Manag Care. 2010;16:678\u201386.","journal-title":"Am J Manag Care"},{"key":"133_CR26","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1001\/jamainternmed.2013.2921","volume":"173","author":"JD Wright","year":"2013","unstructured":"Wright JD, Neugut AI, Ananth CV, Lewin SN, Wilde ET, Lu YS, et al. Deviations from guideline-based therapy for febrile neutropenia in cancer patients and their effect on outcomes. JAMA Intern Med. 2013;173:559\u201368.","journal-title":"JAMA Intern Med"},{"key":"133_CR27","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1524-4733.2007.00242.x","volume":"11","author":"A Eldar-Lissai","year":"2008","unstructured":"Eldar-Lissai A, Cosler LE, Culakova E, Lyman GH. Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value Health. 2008;11:172\u20139.","journal-title":"Value Health"},{"key":"133_CR28","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/jnci\/85.6.488","volume":"85","author":"GH Lyman","year":"1993","unstructured":"Lyman GH, Lyman CG, Sanderson RA, Balducci L. Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. J Natl Cancer Inst. 1993;85:488\u201393.","journal-title":"J Natl Cancer Inst"},{"key":"133_CR29","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0959-8049(95)00468-8","volume":"32A","author":"CA Uyl-de Groot","year":"1996","unstructured":"Uyl-de Groot CA, Vellenga E, Rutten FF. An economic model to assess the savings from a clinical application of haematopoietic growth factors. Eur J Cancer. 1996;32A:57\u201362.","journal-title":"Eur J Cancer"},{"key":"133_CR30","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/978-1-59259-747-5_21","volume-title":"Economics of hematopoietic growth factors in hematopoietic growth factors in oncology: basic science and clinical therapeutics","author":"GH Lyman","year":"2004","unstructured":"Lyman GH, Kuderer NM. Economics of hematopoietic growth factors. In: Morstyn G, Foote M, Lieschke GJ, editors. Economics of hematopoietic growth factors in hematopoietic growth factors in oncology: basic science and clinical therapeutics. Totowa: Humana Press Inc; 2004. p. 409\u201343."},{"key":"133_CR31","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2165\/11589440-000000000-00000","volume":"30","author":"RI Griffiths","year":"2012","unstructured":"Griffiths RI, Barron RL, Gleeson ML, Danese MD, O\u2019Hagan A, Chia VM, et al. Granulocyte-colony stimulating factor use and medical costs after initial adjuvant chemotherapy in older patients with early-stage breast cancer. Pharmacoeconomics. 2012;30:103\u201318.","journal-title":"Pharmacoeconomics"},{"key":"133_CR32","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s00520-012-1589-2","volume":"21","author":"S Lee","year":"2013","unstructured":"Lee S, Knox A, Zeng IS, Coomarasamy C, Blacklock H, Issa S. Primary prophylaxis with granulocyte colony-stimulating factor (GCSF) reduces the incidence of febrile neutropenia in patients with non-hodgkin lymphoma (NHL) receiving CHOP chemotherapy treatment without adversely affecting their quality of life: cost-benefit and quality of life analysis. Support Care Cancer. 2013;21:841\u20136.","journal-title":"Support Care Cancer"},{"key":"133_CR33","first-page":"150","volume":"19","author":"SJ Rajan","year":"2013","unstructured":"Rajan SJ, Carpenter WR, Stearns SC, Lyman GH. Short-term costs associated with primary prophylactic G-CSF use during chemotherapy. Am J Manag Care. 2013;19:150\u20139.","journal-title":"Am J Manag Care"},{"key":"133_CR34","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3109\/10428199509051714","volume":"17","author":"G Dranitsaris","year":"1995","unstructured":"Dranitsaris G, Sutcliffe SB. Economic analysis of prophylactic G-CSF after mini-BEAM salvage chemotherapy for Hodgkin\u2019s and non-Hodgkin\u2019s lymphoma. Leuk Lymphoma. 1995;17:139\u201345.","journal-title":"Leuk Lymphoma"},{"key":"133_CR35","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3109\/10428199709058605","volume":"26","author":"R Bassan","year":"1997","unstructured":"Bassan R, Lerede T, Di Bona E, Rossi G, Pogliani E, Rambaldi A, et al. Granulocyte colony-stimulating factor (G-CSF, filgrastim) after or during an intensive remission induction therapy for adult acute lymphoblastic leukaemia: effects, role of patient pretreatment characteristics, and costs. Leuk Lymphoma. 1997;26:153\u201361.","journal-title":"Leuk Lymphoma"},{"key":"133_CR36","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1093\/jnci\/djt182","volume":"105","author":"N Lathia","year":"2013","unstructured":"Lathia N, Isogai PK, De Angelis C, Smith TJ, Cheung M, Mittmann N, et al. Cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against febrile neutropenia in lymphoma patients. J Natl Cancer Inst. 2013;105:1078\u201385.","journal-title":"J Natl Cancer Inst"},{"key":"133_CR37","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1093\/jnci\/djj305","volume":"98","author":"MJ Hassett","year":"2006","unstructured":"Hassett MJ, O\u2019Malley AJ, Pakes JR, Newhouse JP, Earle CC. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst. 2006;98:1108\u201317.","journal-title":"J Natl Cancer Inst"},{"key":"133_CR38","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/jnci\/djj492","volume":"98","author":"A Russo","year":"2006","unstructured":"Russo A, Autelitano M, Bisanti L. Re: frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst. 2006;98:1826\u20137.","journal-title":"J Natl Cancer Inst"},{"key":"133_CR39","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.1200\/JCO.2002.05.088","volume":"20","author":"XL Du","year":"2002","unstructured":"Du XL, Osborne C, Goodwin JS. Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J Clin Oncol. 2002;20:4636\u201342.","journal-title":"J Clin Oncol"},{"key":"133_CR40","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00520-010-0816-y","volume":"18","author":"M Aapro","year":"2010","unstructured":"Aapro M, Crawford J, Kamioner D. Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now? Support Care Cancer. 2010;18:529\u201341.","journal-title":"Support Care Cancer"},{"key":"133_CR41","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00277-008-0447-2","volume":"87","author":"R Pettengell","year":"2008","unstructured":"Pettengell R, Schwenkglenks M, Bosly A. Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy. Ann Hematol. 2008;87:429\u201330.","journal-title":"Ann Hematol"},{"key":"133_CR42","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10549-008-0018-1","volume":"114","author":"I Chirivella","year":"2009","unstructured":"Chirivella I, Bermejo B, Insa A, Perez-Fidalgo A, Magro A, Rosello S, et al. Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients. Breast Cancer Res Treat. 2009;114:479\u201384.","journal-title":"Breast Cancer Res Treat"},{"key":"133_CR43","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00277-007-0399-y","volume":"87","author":"A Bosly","year":"2008","unstructured":"Bosly A, Bron D, Van Hoof A, De Bock R, Berneman Z, Ferrant A, et al. Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Ann Hematol. 2008;87:277\u201383.","journal-title":"Ann Hematol"},{"key":"133_CR44","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.critrevonc.2011.04.010","volume":"81","author":"GH Lyman","year":"2012","unstructured":"Lyman GH, Barron RL, Natoli JL, Miller RM. Systematic review of efficacy of dose-dense versus non-dose-dense chemotherapy in breast cancer, non-hodgkin lymphoma, and non-small cell lung cancer. Crit Rev Oncol Hematol. 2012;81:296\u2013308.","journal-title":"Crit Rev Oncol Hematol"},{"key":"133_CR45","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/ecc.12043","volume":"22","author":"D Almenar Cubells","year":"2013","unstructured":"Almenar Cubells D, Bosch Roig C, Jimenez Orozco E, Alvarez R, Cuervo JM, Diaz Fernandez N. Effectiveness of daily versus non-daily granulocyte colony-stimulating factors in patients with solid tumours undergoing chemotherapy: A multivariate analysis of data from current practice. Eur J Cancer Care (Engl). 2013;22:400\u201312.","journal-title":"Eur J Cancer Care (Engl)"},{"key":"133_CR46","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s10549-006-9254-4","volume":"100","author":"M Shayne","year":"2006","unstructured":"Shayne M, Crawford J, Dale DC, Culakova E, Lyman GH, ANC Study Group. Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy. Breast Cancer Res Treat. 2006;100:255\u201362.","journal-title":"Breast Cancer Res Treat"},{"key":"133_CR47","doi-asserted-by":"crossref","first-page":"400","DOI":"10.7326\/0003-4819-147-6-200709180-00010","volume":"147","author":"L Sung","year":"2007","unstructured":"Sung L, Nathan PC, Alibhai SM, Tomlinson GA, Beyene J. Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Ann Intern Med. 2007;147:400\u201311.","journal-title":"Ann Intern Med"},{"key":"133_CR48","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/jnci\/djr152","volume":"103","author":"AL Potosky","year":"2011","unstructured":"Potosky AL, Malin JL, Kim B, Chrischilles EA, Makgoeng SB, Howlader N, et al. Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes. J Natl Cancer Inst. 2011;103:979\u201382.","journal-title":"J Natl Cancer Inst"},{"key":"133_CR49","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood-2003-06-2095","volume":"104","author":"M Pfreundschuh","year":"2004","unstructured":"Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rube C, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood. 2004;104:634\u201341.","journal-title":"Blood"},{"key":"133_CR50","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1182\/blood-2003-06-2094","volume":"104","author":"M Pfreundschuh","year":"2004","unstructured":"Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rudolph C, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood. 2004;104:626\u201333.","journal-title":"Blood"},{"key":"133_CR51","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1200\/JCO.2003.09.081","volume":"21","author":"ML Citron","year":"2003","unstructured":"Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial C9741\/cancer and leukemia group B trial 9741. J Clin Oncol. 2003;21:1431\u20139.","journal-title":"J Clin Oncol"},{"key":"133_CR52","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1200\/JCO.1998.16.8.2700","volume":"16","author":"C Chouaid","year":"1998","unstructured":"Chouaid C, Bassinet L, Fuhrman C, Monnet I, Housset B. Routine use of granulocyte colony-stimulating factor is not cost-effective and does not increase patient comfort in the treatment of small-cell lung cancer: an analysis using a Markov model. J Clin Oncol. 1998;16:2700\u20137.","journal-title":"J Clin Oncol"},{"key":"133_CR53","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1385\/MO:22:3:229","volume":"22","author":"N Haim","year":"2005","unstructured":"Haim N, Shulman K, Goldberg H, Tsalic M. The safety of full-dose chemotherapy with secondary prophylactic granulocyte colony stimulating factor (G-CSF) following a prior cycle with febrile neutropenia. Med Oncol. 2005;22:229\u201332.","journal-title":"Med Oncol"},{"key":"133_CR54","doi-asserted-by":"crossref","first-page":"7974","DOI":"10.1200\/JCO.2004.00.7955","volume":"23","author":"JN Timmer-Bonte","year":"2005","unstructured":"Timmer-Bonte JN, de Boo TM, Smit HJ, Biesma B, Wilschut FA, Cheragwandi SA, et al. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study. J Clin Oncol. 2005;23:7974\u201384.","journal-title":"J Clin Oncol"},{"key":"133_CR55","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199107183250305","volume":"325","author":"J Crawford","year":"1991","unstructured":"Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med. 1991;325:164\u201370.","journal-title":"N Engl J Med"},{"key":"133_CR56","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1016\/j.ejca.2010.04.031","volume":"46","author":"C Falandry","year":"2010","unstructured":"Falandry C, Campone M, Cartron G, Guerin D, Freyer G. Trends in G-CSF use in 990 patients after EORTC and ASCO guidelines. Eur J Cancer. 2010;46:2389\u201398.","journal-title":"Eur J Cancer"},{"key":"133_CR57","first-page":"279","volume":"90","author":"K Tamura","year":"1999","unstructured":"Tamura K. Use of granulocyte colony-stimulating factor (G-CSF) in clinical practice in Fukuoka City area in Japan. Fukuoka Igaku Zasshi. 1999;90:279\u201385.","journal-title":"Fukuoka Igaku Zasshi"},{"key":"133_CR58","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1524-4733.2008.00434.x","volume":"12","author":"SD Ramsey","year":"2009","unstructured":"Ramsey SD, Liu Z, Boer R, Sullivan SD, Malin J, Doan QV, et al. Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy. Value Health. 2009;12:217\u201325.","journal-title":"Value Health"},{"key":"133_CR59","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3816\/CLM.2001.n.011","volume":"2","author":"VA Morrison","year":"2001","unstructured":"Morrison VA, Picozzi V, Scott S, Pohlman B, Dickman E, Lee M, et al. The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-hodgkin\u2019s lymphoma receiving initial CHOP chemotherapy: a risk factor analysis. Clin Lymphoma. 2001;2:47\u201356.","journal-title":"Clin Lymphoma"},{"key":"133_CR60","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1200\/JCO.2011.36.8647","volume":"30","author":"KK Chan","year":"2012","unstructured":"Chan KK, Siu E, Krahn MD, Imrie K, Alibhai SM. Cost-utility analysis of primary prophylaxis versus secondary prophylaxis with granulocyte colony-stimulating factor in elderly patients with diffuse aggressive lymphoma receiving curative-intent chemotherapy. J Clin Oncol. 2012;30:1064\u201371.","journal-title":"J Clin Oncol"},{"key":"133_CR61","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2165\/00019053-200725040-00006","volume":"25","author":"LE Cosler","year":"2007","unstructured":"Cosler LE, Eldar-Lissai A, Culakova E, Kuderer NM, Dale D, Crawford J, et al. Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective. Pharmacoeconomics. 2007;25:343\u201351.","journal-title":"Pharmacoeconomics."},{"key":"133_CR62","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/jnci\/93.1.31","volume":"93","author":"R Garcia-Carbonero","year":"2001","unstructured":"Garcia-Carbonero R, Mayordomo JI, Tornamira MV, Lopez-Brea M, Rueda A, Guillem V, et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. J Natl Cancer Inst. 2001;93:31\u20138.","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl 1","key":"133_CR63","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1007\/s11523-011-0190-9","volume":"7","author":"P Gascon","year":"2012","unstructured":"Gascon P. Presently available biosimilars in hematology-oncology: G-CSF. Target Oncol. 2012;7(Suppl 1):S29\u201334.","journal-title":"Target Oncol"},{"key":"133_CR64","first-page":"327","volume":"7","author":"A Gardellini","year":"2013","unstructured":"Gardellini A, Gigli F, Babic A, Andreola G, Radice D, Sammassimo S, et al. Filgrastim XM02 (Tevagrastim\u00ae) after autologous stem cell transplantation compared to lenograstim: favourable cost-efficacy analysis. Ecancermedicalscience. 2013;7:327.","journal-title":"Ecancermedicalscience"},{"key":"133_CR65","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/1078155211407367","volume":"18","author":"M Aapro","year":"2012","unstructured":"Aapro M, Cornes P, Abraham I. Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia. J Oncol Pharm Pract. 2012;18:171\u20139.","journal-title":"J Oncol Pharm Pract"},{"key":"133_CR66","doi-asserted-by":"crossref","first-page":"281","DOI":"10.5414\/CP201633","volume":"50","author":"P Hadji","year":"2012","unstructured":"Hadji P, Kostev K, Schroder-Bernhardi D, Ziller V. Cost comparison of outpatient treatment with granulocyte colony-stimulating factors (G-CSF) in Germany. Int J Clin Pharmacol Ther. 2012;50:281\u20139.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"133_CR67","doi-asserted-by":"crossref","first-page":"625","DOI":"10.2217\/fon.12.32","volume":"8","author":"N Salesi","year":"2012","unstructured":"Salesi N, Di Cocco B, Colonna M, Veltri E. Biosimilar medicines in oncology: single-center experience with biosimilar G-CSF. Future Oncol. 2012;8:625\u201330.","journal-title":"Future Oncol"},{"key":"133_CR68","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1146\/annurev.publhealth.22.1.91","volume":"22","author":"ML Brown","year":"2001","unstructured":"Brown ML, Lipscomb J, Snyder C. The burden of illness of cancer: economic cost and quality of life. Annu Rev Public Health. 2001;22:91\u2013113.","journal-title":"Annu Rev Public Health"},{"key":"133_CR69","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1200\/JCO.2001.19.13.3219","volume":"19","author":"JA Hayman","year":"2001","unstructured":"Hayman JA, Langa KM, Kabeto MU, Katz SJ, DeMonner SM, Chernew ME, et al. Estimating the cost of informal caregiving for elderly patients with cancer. J Clin Oncol. 2001;19:3219\u201325.","journal-title":"J Clin Oncol"},{"key":"133_CR70","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/jnci\/djk001","volume":"99","author":"KR Yabroff","year":"2007","unstructured":"Yabroff KR, Davis WW, Lamont EB, Fahey A, Topor M, Brown ML, et al. Patient time costs associated with cancer care. J Natl Cancer Inst. 2007;99:14\u201323.","journal-title":"J Natl Cancer Inst"},{"key":"133_CR71","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1634\/theoncologist.6-5-441","volume":"6","author":"EA Calhoun","year":"2001","unstructured":"Calhoun EA, Chang CH, Welshman EE, Fishman DA, Lurain JR, Bennett CL. Evaluating the total costs of chemotherapy-induced toxicity: results from a pilot study with ovarian cancer patients. Oncologist. 2001;6:441\u20135.","journal-title":"Oncologist"},{"key":"133_CR72","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3111\/13696990903149016","volume":"12","author":"X Song","year":"2009","unstructured":"Song X, Fowler R, Ruiz K, Hurley D, Barron RL. Impact of neutropenic complications on short-term disability in patients with cancer receiving chemotherapy. J Med Econ. 2009;12:154\u201363.","journal-title":"J Med Econ"},{"key":"133_CR73","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1634\/theoncologist.12-4-478","volume":"12","author":"CL Bennett","year":"2007","unstructured":"Bennett CL, Calhoun EA. Evaluating the total costs of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients. Oncologist. 2007;12:478\u201383.","journal-title":"Oncologist"},{"key":"133_CR74","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1007\/s00520-006-0085-y","volume":"14","author":"JA Sloan","year":"2006","unstructured":"Sloan JA, Frost MH, Berzon R, Dueck A, Guyatt G, Moinpour C, et al. The clinical significance of quality of life assessments in oncology: a summary for clinicians. Support Care Cancer. 2006;14:988\u201398.","journal-title":"Support Care Cancer"},{"key":"133_CR75","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1756-9966-27-32","volume":"27","author":"A Montazeri","year":"2008","unstructured":"Montazeri A. Health-related quality of life in breast cancer patients: a bibliographic review of the literature from 1974 to 2007. J Exp Clin Cancer Res. 2008;27:32.","journal-title":"J Exp Clin Cancer Res"},{"key":"133_CR76","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jama.270.9.1132","volume":"270","author":"EA Jones","year":"1993","unstructured":"Jones EA, Bolyard AA, Dale DC. Quality of life of patients with severe chronic neutropenia receiving long-term treatment with granulocyte colony-stimulating factor. JAMA. 1993;270:1132\u20133.","journal-title":"JAMA"},{"key":"133_CR77","first-page":"1411","volume":"18","author":"MT Fazio","year":"1991","unstructured":"Fazio MT, Glaspy JA. The impact of granulocyte colony-stimulating factor on quality of life in patients with severe chronic neutropenia. Oncol Nurs Forum. 1991;18:1411\u20134.","journal-title":"Oncol Nurs Forum"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-014-0133-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-014-0133-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-014-0133-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T22:06:43Z","timestamp":1598047603000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-014-0133-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":77,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["133"],"URL":"https:\/\/doi.org\/10.1007\/s12325-014-0133-9","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7]]}}}